ClinicalTrials.gg
WithdrawnNCT05217472Updated Feb 1, 2022

An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)

A Phase 2 interventional study of Ravaglimab and Ravagalimab in Sjogren's Syndrome (SS), sponsored by AbbVie. Withdrawn at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-02-01.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study canceled

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Sjogren's Syndrome with a site in Netherlands — 3 open to participants now, 5 under way, 3 of them phase 3. Sjogren's Syndrome · Netherlands.

Enrollment
18th of 18
0 · median 120
Started
2020
with 1 other
Phase 2
9 of 18
1 open now
Registered
9th of 18
by date
Lead sponsor
1 of 18
AbbVie

Among the 18 studies in Sjogren's Syndrome with a site in Netherlands, this one is the 18th largest by enrollment, is one of 2 that started in 2020, is one of 9 in phase 2, and was the 9th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

3 of the 18 studies in Sjogren's Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Sjogren's Syndrome with a site in Netherlands, or all of them as a file.
02

Study summary

Sjogren's syndrome (SS) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement. In addition, a variety of systemic manifestations may occur; including fatigue, musculoskeletal symptoms, rashes, and internal organ (e.g., pulmonary, renal, hepatic, and neurologic) disease. Sjogren's syndrome may occur in isolation, primary Sjogren's syndrome (pSS), or in a secondary form, often associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or systemic sclerosis. Ravagalimab is an investigational drug being developed to help treat patients with inflammatory diseases like SS. This study will evaluate how well ravagalimab works within the body and how safe it is in patients with primary SS (pSS).

Ravagalimab, a potent CD40 antagonist is an investigational drug being developed for the treatment of Sjogren's syndrome (SS). This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Participants 18-75 years of age with Sjogren's syndrome (SS) will be enrolled. Around 45 participants will be enrolled in the study in multiple sites within Netherlands.

Participants will receive ravagalimab intravenous (IV) loading dose or IV placebo at baseline followed by subcutaneous (SC) ravagalimab or matching placebo for 22 weeks.

There will be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, labial gland (lip) biopsy, and checking for side effects and completing questionnaires.

03

Conditions studied

  • Sjogren's Syndrome (SS)

Browse trials for

Keywords

  • Sjogren's Syndrome (SS)
  • Primary Sjogren's Syndrome (pSS)
  • Ravagalimab
  • ABBV-323
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary Sjogren's syndrome (pSS) diagnosed according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2016 Criteria.
  • Lymphocyte focus score (local lymphocytic infiltrates) >= 1 in sublabial salivary gland specimen. Subjects with sublabial salivary gland obtained 3 months prior to Screening and meeting this criterion will be eligible without a biopsy at Screening. Subjects without a sublabial salivary gland biopsy within 3 months of Screening will obtain a biopsy for a lymphocyte focus score at Screening.
  • EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) >= 5 at Screening.
  • EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) >= 6 at Screening.

Exclusion criteria

Exclusion Criteria:

  • History of drug or alcohol abuse within the last 6 months.
  • History of an allergic reaction or significant sensitivity to constituents of the study drug (and its ), the ingredients of Chinese hamster ovary cells and/or other products in the same class.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Ravagalimab

    Participants will receive a loading dose of intravenous (IV) ravagalimab dose A at Week 0 followed by subcutaneous (SC) ravagalimab dose A every other week (eow)

    Drug: Ravaglimab · Drug: Ravagalimab

  • Placebo comparator
    Placebo

    Participants will receive a loading dose of intravenous (IV) placebo at Week 0 followed by subcutaneous (SC) placebo every other week (eow)

    Drug: Placebo

Interventions

  • Intravenous Injection

    Also known as: ABBV-323

  • Subcutaneous Injection

    Also known as: ABBV-323

  • DrugPlacebo

    Intravenous Injection

  • DrugPlacebo

    Subcutaneous Injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)

    ESSDAI is a systemic disease activity index including 12 domains (i.e., organ systems: cutaneous, respiratory, renal, articular, muscular, peripheral nervous system, central nervous system, haematological, glandular, constitutional, lymphadenopathic and biological).

    Time frame: Week 24

Secondary outcomes

  1. Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)

    ESSDAI is a systemic disease activity index including 12 domains (i.e., organ systems: cutaneous, respiratory, renal, articular, muscular, peripheral nervous system, central nervous system, haematological, glandular, constitutional, lymphadenopathic and biological).

    Time frame: Up to Week 16

  2. Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)

    ESSPRI is designed to evaluate the patient symptoms with 3 questions related to the dryness, pain and fatigue a participant has experienced in the prior 2 weeks. It is a numeric rating scale from 0 - 10, with a final score the mean of the 3 questions

    Time frame: Up to Week 24

  3. Change From Baseline in Tender Joint Count

    An assessment of 68 joints will be done for tenderness by pressure manipulation on physical examination. Joint pain/tenderness will be classified as: present, absent, replaced or no assessment.

    Time frame: Up to Week 24

  4. Change From Baseline in Swollen Joint Count

    An assessment of 66 joints will be done by directed physical examination. The joints to be examined for swelling are the same as those examined for tenderness, except the hip joints are excluded. Joint swelling will be classified as present, absent, replaced or no assessment.

    Time frame: Up to Week 24

  5. Change From Baseline in Salivary Flow (Unstimulated)

    Patients will be asked to collect their saliva in a cup every 30 seconds for a total period of 5 minutes. The saliva production is expressed in ml/minute.

    Time frame: Up to Week 24

  6. Change From Baseline in Salivary Flow (Stimulated)

    Saliva production is stimulated by parafilm and collected in a cup every 30 seconds for a total period of 5 minutes.. The saliva production is expressed in ml/minute.

    Time frame: Up to Week 24

  7. Change From Baseline in Lacrimal Flow (Schirmer's Test of Ocular Function)

    Lachrymal flow will be assessed by Schirmer's test of ocular function. A small filter paper will be placed in the conjunctival sac for 5 minutes. After that, the degree of wetting is evaluated

    Time frame: Up to Week 24

  8. Change From Baseline in Van Bijsterveld Score

    The van Bijsterveld score is an ocular score for dryness. The Bijsterveld score is determined by adding up the combined score (from 0 to 3; 0 is normal and 3 is the highest level of staining) in the central and two outer sections of the eye.

    Time frame: Up to Week 24

  9. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

    FACIT-Fatigue is a 13-item questionnaire that evaluates fatigue/tiredness and its impact on daily activities and functioning in chronic diseases. This instrument includes items such as tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily functioning (e.g., sleeping, and social activities). A lower score indicates less negative impact on daily activities.

    Time frame: Up to Week 24

  10. Change From Baseline in Patient's Global Assessment of Disease Activity Numeric Rating Scales

    Patient's Global Assessment of Disease Activity Numeric Rating Scale allows a patient to score 0 - 10 to assess the patient's overall functionality assessment considering the disease activity within the past week

    Time frame: Up to Week 24

  11. Change From Baseline in Physician's Global Assessment of Disease Activity Numeric Rating Scales

    Physician's Global Assessment of Disease Activity Numeric Rating Scale allows a physician to score 0 - 10 to assess the patient's overall functionality assessment considering the disease activity within the past week.

    Time frame: Up to Week 24

  12. Change from Baseline in anti-Sjogrens-syndrome-related antigen A (anti-SSA)

    Change from baseline in anti-SSA s assessed.

    Time frame: Up to Week 24

  13. Change from Baseline in anti-Sjogrens-syndrome-related antigen B (anti-SSB)

    Change from baseline in anti-SSB is assessed.

    Time frame: Up to Week 24

  14. Change from Baseline in antinuclear antibody (ANA)

    Change from baseline in antinuclear antibody (ANA) is assessed.

    Time frame: Up to Week 24

  15. Change from Baseline in rheumatoid factor (RF)

    Change from baseline in rheumatoid factor (RF) is assessed.

    Time frame: Up to Week 24

  16. Change from Baseline in high-sensitivity C-reactive protein (hsCRP)

    Change from baseline in high-sensitivity C-reactive protein (hsCRP) is assessed.

    Time frame: Up to Week 24

  17. Change from Baseline in immunoglobulin M (IgM)

    Change from baseline in immunoglobulin M (IgM) is assessed

    Time frame: Up to Week 24

  18. Change from Baseline in immunoglobulin M (IgG)

    Change from baseline in immunoglobulin M (IgG) is assessed.

    Time frame: Up to Week 24

  19. Change from Baseline in immunoglobulin A (IgA)

    Change from baseline in immunoglobulin A (IgA) is assessed.

    Time frame: Up to Week 24

  20. Change from Baseline in Serum-Free Light Chains

    Change from baseline in serum-free light chains is assessed.

    Time frame: Up to Week 24

  21. Change from Baseline in Serum C3

    Change from baseline in Serum C3 is assessed.

    Time frame: Up to Week 24

  22. Change from Baseline in Serum C4

    Change from baseline in Serum C4 is assessed.

    Time frame: Up to Week 24

  23. Change from Baseline in Haemolytic Complement CH50

    Change from baseline in CH50 is assessed.

    Time frame: Up to Week 24

  24. Change From Baseline in Focus Score of Sublabial Salivary Gland Biopsy (In Participants With a Screening and Week 24 Biopsy)

    Change from baseline in focus score of sublabial salivary gland biopsy is assessed.

    Time frame: Week 24

07

Study locations

1 site
  • Universitair Medisch Centrum Utrecht /ID# 214029
    Utrecht, 3584 CX, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2020; primary completion for Apr 2022, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2020
First posted
Feb 1, 2022
StartEst.
Mar 6, 2020
Primary completionEst.
Apr 15, 2022
CompletionEst.
May 15, 2022
Last update
Feb 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05217472
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 1, 2022
Start date
Mar 6, 2020 (estimated)
Primary completion
Apr 15, 2022 (estimated)
Completion
May 15, 2022 (estimated)
Last update
Feb 1, 2022

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravagalimab

Start the discussion